Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Orr Limpisvasti

Sports Medicine Los Angeles, CA Medical Doctor

NPI 1376514984 CMS profile 288633

6801 Park Ter Ste 100, Los Angeles, CA 90045

Open in the dashboard

General payments

$334,567

291 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Orr Limpisvasti of Los Angeles, CA is reported in the CMS Open Payments database as having received $334,567 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $91,625 52
2024 General $42,196 27
2023 General $36,407 31
2022 General $26,423 19
2021 General $22,822 15
2020 General $42,174 49
2019 General $72,920 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Orr Limpisvasti
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Orr Limpisvasti were reported at $91,625. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Orr Limpisvasti Sports Medicine median Middle half National median
2019 $72,920 $1,176 $199–$4,249 $163
2020 $42,174 $708 $96–$2,890 $114
2021 $22,822 $1,213 $152–$3,994 $132
2022 $26,423 $1,230 $159–$3,998 $149
2023 $36,407 $584 $146–$2,836 $160
2024 $42,196 $628 $163–$3,168 $164
2025 $91,625 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $234,884 249 payments
  2. Linvatec Corporation $94,856 26 payments
  3. Micromed Inc $2,842 3 payments
  4. Saxum Surgical, Inc. $1,532 3 payments
  5. Vericel Corporation $242 6 payments
  6. Smith+Nephew, Inc. $194 3 payments
  7. Cartiheal (2009) LTD. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $137,851 35 payments
  2. Royalty or License $105,301 36 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $51,583 9 payments
  4. Travel and Lodging $30,806 94 payments
  5. Food and Beverage $4,985 113 payments
  6. Education $4,042 4 payments
Products named General payments · program years 2019–2025
  1. LINVATEC KNEE PRESERVATION SYSTEM $44,498 11 payments
  2. KNEE BIOLOGICS $39,339 12 payments
  3. Arthrex Knee & Hip - Instruments - Hand Instruments - Nano - Other $26,466 9 payments
  4. LINVATEC HIP PRESERVATION SYSTEM $11,019 3 payments
  5. Arthrex Upper Extremity - Suture - SutureTape - SutureTag - 1.3mm $1,134 1 payment
  6. CAPITAL CONSUMABLES CONSUMABLES RF BRF $1,069 2 payments
  7. Arthrex Upper Extremity - Suture - SutureTape - SutureTag $971 3 payments
  8. Arthrex Knee & Hip - Instruments - Hand Instruments - Nano $710 1 payment
  9. SHOULDER IMPLANTS FIBERTAK KNOTLESS $580 2 payments
  10. SHOULDER INSTRUMENTS HAND INSTRUMENTS GRASPERS & RETRIEVERS $500 1 payment
  11. Other $3,033 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Orthopedic Surgery: 203

Drug cost

$348

Median for Orthopedic Surgery: $1,433

Branded share of claims

100%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Er Diclofenac Sodium Brand 12 $348

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$15,073

Medicare's payments for the services billed

Medicare patients

65

Average age 69

Services billed

154

24 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 65%
High blood pressure 60%
Diabetes 20%
Ischemic heart disease 17%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record